KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Work In Process: 2010-2020

Historic Work In Process for Biomarin Pharmaceutical (BMRN) over the last 11 years, with Dec 2020 value amounting to $308.3 million.

  • Biomarin Pharmaceutical's Work In Process rose 39.01% to $412.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $412.4 million, marking a year-over-year increase of 39.01%. This contributed to the annual value of $308.3 million for FY2020, which is 11.91% down from last year.
  • According to the latest figures from FY2020, Biomarin Pharmaceutical's Work In Process is $308.3 million, which was down 11.91% from $350.0 million recorded in FY2019.
  • Over the past 5 years, Biomarin Pharmaceutical's Work In Process peaked at $350.0 million during FY2019, and registered a low of $167.8 million during FY2016.
  • Moreover, its 3-year median value for Work In Process was $308.3 million (2020), whereas its average is $296.4 million.
  • In the last 5 years, Biomarin Pharmaceutical's Work In Process surged by 51.46% in 2019 and then decreased by 11.91% in 2020.
  • Biomarin Pharmaceutical's Work In Process (Yearly) stood at $167.8 million in 2016, then surged by 39.86% to $234.7 million in 2017, then fell by 1.54% to $231.1 million in 2018, then soared by 51.46% to $350.0 million in 2019, then decreased by 11.91% to $308.3 million in 2020.